Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat.
Achim Fritsch, Michaela Meyer, Robert O Blaustein...
https://pubmed.ncbi.nlm.nih.gov/38916717/Actively Recruiting
Led by Merck Sharp & Dohme LLC · Updated on 2026-10-30
342
Participants Needed
111
Research Sites
142 weeks
Total Duration
Researchers are evaluating the effects of vericiguat compared to placebo in children and adolescents with heart failure caused by left ventricular systolic dysfunction. The study aims to determine if vericiguat can better reduce levels of a heart failure marker called NT-proBNP over 16 weeks. This research is a Phase 23 clinical trial assessing efficacy, safety, and pharmacokinetics in pediatric participants. Participants receive either vericiguat or placebo daily by mouth in tablet or suspension form for 52 weeks during the Base Period. After completing this phase, eligible participants can join an optional open-label Extension Period where they receive vericiguat daily. The study incorporates a previously separate extension arm, allowing long-term follow-up of up to approximately 8 years. Throughout the study, participants will have their NT-proBNP levels measured and monitored at various time points, including baseline, Week 16, Week 52, and during the Extension Period. Researchers will also track adverse events and reasons for stopping the study drug. Additional assessments include heart failure events, pharmacokinetic measurements, and safety evaluations. The total study duration can extend up to 8 years for some participants.
CONDITIONS
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
T
Toll Free Number
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Merck Sharp & Dohme LLC
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Vericiguat | Placebo |
|---|---|---|
| What is it? | Oral vericiguat administered once daily in tablet or suspension form at pediatric-appropriate doses in children with chronic heart failure due to systolic dysfunction. | Matching oral placebo (tablet or suspension) given once daily to children in the control group. |
| Role in the trial | Investigational active drug being tested for efficacy, safety, and pharmacokinetics in pediatric heart failure. | Placebo control to compare against the investigational drug. |
| Primary use | To evaluate the effect of vericiguat on NT‑proBNP levels, safety, and drug pharmacokinetics in children with systolic heart failure. | To serve as control for assessing the same outcomes under placebo. |
| How it is given or performed | Once‑daily oral administration using tablet or suspension formulations at age‑appropriate doses. | Once‑daily oral administration of matching placebo in tablet or suspension form. |
| Evidence status | Efficacy in pediatric heart failure is unestablished and under investigation. | Placebo has no active therapeutic effect and serves as control. |
| Important risks | Safety in this pediatric population is being assessed, including adverse events and treatment discontinuations. | Safety in placebo‑treated children is monitored in the same manner. |
| Important limitations | Limited to pediatric patients with LVEF <45%. Results may not apply to those with preserved ejection fraction or different heart failure etiologies. | Same population limitations apply; placebo arm findings are applicable only within trial constraints. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 52 weeks
Participants take either vericiguat or placebo orally once daily in tablet or suspension form for 52 weeks.
Regular visits during treatment period
Duration - Up to 8 years
Eligible participants can join an open-label extension where they receive vericiguat daily and are monitored for safety and effects for up to approximately 8 years.
Periodic safety and efficacy assessments
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Achim Fritsch, Michaela Meyer, Robert O Blaustein...
https://pubmed.ncbi.nlm.nih.gov/38916717/Merck Sharp & Dohme LLC
Lead Sponsor